Dynavax Technologies reported $10.78M in EBITDA for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Adma Biologics ADMA:US $ -14.26M 0.39M
Agenus AGEN:US $ -64.67M 25.03M
Alexion Pharmaceuticals ALXN:US $ 892.3M 186.4M
Amgen AMGN:US $ 3188M 218M
AstraZeneca AZN:LN 2149M 322M
Astrazeneca AZN:US $ 2149M 322M
Biogen BIIB:US $ 1147.6M 41.7M
Biomarin Pharmaceutical BMRN:US $ 41.16M 14.24M
BioSpecifics Technologies BSTC:US 6.54 6.76
Bristol Myers Squibb BMY:US $ 5679M 455M
Chimerix CMRX:US $ -17.78M 3.29M
Dynavax Technologies DVAX:US $ 10.78M 19.34M
Gilead Sciences GILD:US $ 2816M 669M
Glaxosmithkline GSK:US $ 2626M 584M
Gw Pharmaceuticals GWPH:US $ -17.18M 2.02M
Idera Pharmaceuticals IDRA:US $ -6.36M 3.66M
Minerva Neurosciences NERV:US $ -8.96M 1.46M
Nektar Therapeutics NKTR:US $ -106.66M 0.81M
Neurocrine Biosciences NBIX:US $ 70.4M 36.4M
Novartis NOVN:VX SF 4772M 423M
Pfizer PFE:US $ 7593M 610M
Regeneron Pharmaceuticals REGN:US $ 3418.3M 2238.2M
Sarepta Therapeutics SRPT:US $ -159.13M 26.19M
Vertex Pharmaceuticals VRTX:US $ -5.12M 917.88M